Risk–benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study

Simple item page
dc.contributor.authorSeree-aphinan C.
dc.contributor.authorSuchonwanit P.
dc.contributor.authorRattanakaemakorn P.
dc.contributor.authorPomsoong C.
dc.contributor.authorRatanapokasatit Y.
dc.contributor.authorSetthaudom C.
dc.contributor.authorSuangtamai T.
dc.contributor.authorChanprapaph K.
dc.contributor.otherMahidol University
dc.date.accessioned2023-05-19T07:49:46Z
dc.date.available2023-05-19T07:49:46Z
dc.date.issued2023-05-01
dc.identifier.citationJournal of the European Academy of Dermatology and Venereology Vol.37 No.5 (2023) , e572-e575
dc.identifier.doi10.1111/jdv.18890
dc.identifier.eissn14683083
dc.identifier.issn09269959
dc.identifier.pmid36662625
dc.identifier.scopus2-s2.0-85147389245
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/82060
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleRisk–benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study
dc.typeLetter
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85147389245&origin=inward
oaire.citation.endPagee575
oaire.citation.issue5
oaire.citation.startPagee572
oaire.citation.titleJournal of the European Academy of Dermatology and Venereology
oaire.citation.volume37
oairecerif.author.affiliationRamathibodi Hospital

Files

Collections

Scopus 2023